



---

*'Aridis Awarded National Institutes of Health (NIH) Contract to Develop Gallium-Based Anti-Infectives'*

October 30th, 2013 (San Jose, CA). Aridis Pharmaceuticals announced today that it had received a contract worth up to \$17.4M from the National Institute of Allergy and Infectious Diseases (NIAID) part of the NIH, to develop a novel anti-infective based on gallium complexes to treat Category A & B bacterial agents and other public health pathogens. The contract will also result in the development of advanced aerosol formulations to facilitate rapid deployment.

"We are pleased to work with NIAID to develop a new class of broad spectrum anti-infectives for biodefense and public health applications" said Dr. Vu Truong, the principal investigator for the award and Aridis' Chief Scientific Officer. "This contract award is gratifying as it represents the culmination of many years of research on gallium based anti-infective, leading to recognition by an expert scientific review panel that this class of anti-infective is promising" said Dr. Truong. "There is a well-recognized shortage of new anti-infectives to combat the growing problem of antibiotic drug resistance. This contract will enable us to further advance the development of novel gallium based complexes to address this global problem" said Eric Patzer, President of Aridis. "The current award further underscores Aridis' strength in anti-infective drug development and its novel product portfolio to fight infection" said Dr. Truong. This contract is designed to fund the completion of pre-clinical development, IND, and clinical testing.

#### About Aridis

Aridis is a privately held biotechnology company applying proprietary stabilization formulation and drug delivery technologies to produce novel infectious disease focused therapies. Aridis' product pipeline includes AR-301 anti-*Staphylococcus aureus* human monoclonal antibody to treat acute pneumonia, AR-101 anti-*Pseudomonas aeruginosa* LPS human monoclonal antibody, Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi, Aerucin™, a broadly reactive monoclonal antibody against *Pseudomonas aeruginosa* initially being developed to treat acute pneumonia, and AR-401 anti-*Acinetobacter baumannii* human monoclonal antibody.

#### Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of AR-301, AR-101, Panaecin™, Aerucin™, AR-401, Aridis proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

For more information, please contact:  
Eric Patzer  
President of Aridis

408-385-1742.  
Source: Aridis, LLC.